Media ReleasesImugene Limited

View All Imugene Limited News


Imugene announces Imugene’s Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx Immunotherapy Clinical Development Plan

Sydney, Australia, 20 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it had received and accepted the minutes of its Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its KEY-Vaxx cancer immunotherapy on 8 February 2019.

Imugene Managing Director and Chief Executive Officer Leslie Chong said, “The meeting was productive and provided Imugene with a clear roadmap for a successful IND submission and subsequent clinical development of KEY-Vaxx.”

For further information please download PDF attached:
Download this document